Comparative evaluation of triplet antiemetic schedule versus doublet antiemetic schedule in chemotherapy-induced emesis in head and neck cancer patients.

about

Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy?-a systematic review and meta-analysis.

P2860

Q38598421-D6114F66-4DB7-4092-9366-BAE11307EEF2

P2860

Comparative evaluation of triplet antiemetic schedule versus doublet antiemetic schedule in chemotherapy-induced emesis in head and neck cancer patients.

Item

http://www.wikidata.org/entity/Q36093627

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Comparative evaluation of trip ...... head and neck cancer patients.

@ast

Comparative evaluation of trip ...... head and neck cancer patients.

@en

type

Item

label

Comparative evaluation of trip ...... head and neck cancer patients.

@ast

Comparative evaluation of trip ...... head and neck cancer patients.

@en

prefLabel

Comparative evaluation of trip ...... head and neck cancer patients.

@ast

Comparative evaluation of trip ...... head and neck cancer patients.

@en

P1476

Comparative evaluation of trip ...... head and neck cancer patients.

@en

P2093

Abhishek Soni

http://www.w3.org/2001/XMLSchema#string

Pulkit Kaushal

http://www.w3.org/2001/XMLSchema#string

Rajeev Atri

http://www.w3.org/2001/XMLSchema#string

Vivek Kaushal

http://www.w3.org/2001/XMLSchema#string

P2860

A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy.

Antiemetics: American Society of Clinical Oncology clinical practice guideline update.

Palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy.

Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.

5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial.

Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patients.

Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting.

Combination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in lung cancer patients receiving multiple cycles of cisplatin-based chemotherapy.

Prevention of postoperative nausea and vomiting.

Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.

P304

567

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3332/ECANCER.2015.567

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-08-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

281309406

http://www.w3.org/2001/XMLSchema#string

P698

26435740

http://www.w3.org/2001/XMLSchema#string

P932

4583242

http://www.w3.org/2001/XMLSchema#string

Comparative evaluation of triplet antiemetic schedule versus doublet antiemetic schedule in chemotherapy-induced emesis in head and neck cancer patients.

about

P2860

P2860

Comparative evaluation of triplet antiemetic schedule versus doublet antiemetic schedule in chemotherapy-induced emesis in head and neck cancer patients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P932